Forward Science Awarded Gsa Contract

(Houston, TX) On July 1, 2020, Forward Science, a privately held MedTech company founded in Stafford, Texas, was awarded a GSA contract. The contract includes approval for the company’s flagship product, OralID, as well as Forward Science’s treatment and therapeutics line, SalivaMAX and Orapeutic.

Since launching in 2012, Forward Science’s vision has been to innovate technologies into simple, efficient, and more affordable options that change lives. Receiving GSA contract approval allows Forward Science’s products to become much more accessible to patients that previously did not have the resources or access to them beforehand. “It is gratifying that the government has recognized the safety and efficacy of our products. We are grateful to have the government acknowledging the need for our products through the GSA contract,” said Brian Pikkula, Chief Scientific Officer of Forward Science.

Forward Science has been working to receive a GSA contract for quite some time. “This is a big step for Forward Science and for patients across the US,” said CEO, Robert Whitman. “Now we are able to reach patients that we haven’t been able to reach before—a lot of which are patients that need these products the most. We are excited to expand the network of patients we are able to assist.” Moving forward, Forward Science can begin selling OralID, SalivaMAX, and Orapeutic to more government-affiliated healthcare providers, increasing the network of patients that will benefit from these products. For more information on accessing Forward Science’s products, email info@forwardscience.com.

About Forward Science
Forward Science is a privately held MedTech company based in Houston, Texas. OralID, Forward Science’s flagship product, is an award-winning oral cancer screening device that allows clinicians to visualize abnormalities that may not be seen under traditional white light examinations. With the success of OralID, Forward Science continued to focus on moving science forward in the oral healthcare industry by launching advanced diagnostic testing products (CytID, hpvID, phID, PathID) along with treatment options (SalivaMAX and Orapeutic). In addition to developing proprietary, state-of-the-art products, Forward Science has partnered with industry leaders to provide new and effective solutions to the dental community. Forward Science designs, develops, and manufactures their products in-house, ensuring the highest quality of standards coupled with superior customer service. Forward Science has quickly evolved into the industry leader for providing oral healthcare products worldwide.

To learn more about any of Forward Science’s products, please visit www.ForwardScience.com or call 855-696-7254.